Celldex Therapeutics, Inc. (CLDX) Analysts See $-0.12 EPS

July 14, 2018 - By Nadine Davis

Analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report $-0.12 EPS on August, 14.They anticipate $0.11 EPS change or 47.83 % from last quarter’s $-0.23 EPS. After having $-0.19 EPS previously, Celldex Therapeutics, Inc.’s analysts see -36.84 % EPS growth. The stock increased 0.12% or $0.0006 during the last trading session, reaching $0.5206. About 1.26 million shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 79.56% since July 14, 2017 and is downtrending. It has underperformed by 92.13% the S&P500.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Among 4 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Celldex Therapeutics had 4 analyst reports since March 8, 2018 according to SRatingsIntel. On Thursday, March 8 the stock rating was maintained by Jefferies with “Hold”. Leerink Swann maintained the shares of CLDX in report on Thursday, March 8 with “Market Perform” rating. The firm has “Neutral” rating given on Tuesday, April 17 by Cantor Fitzgerald. The company was downgraded on Monday, April 16 by Cowen & Co.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $74.65 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

More recent Celldex Therapeutics, Inc. (NASDAQ:CLDX) news were published by: Seekingalpha.com which released: “Celldex Therapeutics Salvage Value” on June 15, 2018. Also Fool.com published the news titled: “Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics” on June 29, 2018. Nasdaq.com‘s news article titled: “How David Gardner’s Biggest Losers Demonstrate Why Long-Term Investing Wins” with publication date: July 02, 2018 was also an interesting one.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: